Scott W Canna

List of Publications by Year
in descending order

58 papers	6,931 citations	136950 32 h-index	168389 53 g-index
65 all docs	65 docs citations	65 times ranked	8865 citing authors

#	Article	IF	Citations
1	Neonatal-Onset Multisystem Inflammatory Disease Responsive to Interleukin-1Î² Inhibition. New England Journal of Medicine, 2006, 355, 581-592.	27.0	853
2	An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome. Nature Genetics, 2014, 46, 1140-1146.	21.4	585
3	On the Alert for Cytokine Storm: Immunopathology in <scp>COVID</scp>â€19. Arthritis and Rheumatology, 2020, 72, 1059-1063.	5.6	562
4	Hyperferritinemia and inflammation. International Immunology, 2017, 29, 401-409.	4.0	385
5	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 1. Arthritis and Rheumatology, 2020, 72, 1791-1805.	5.6	323
6	Repeated TLR9 stimulation results in macrophage activation syndromeâ€“like disease in mice. Journal of Clinical Investigation, 2011, 121, 2264-2277.	8.2	315
7	American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARSâ€“CoVâ€2 and Hyperinflammation in Pediatric COVIDâ€19: Version 2. Arthritis and Rheumatology, 2021, 73, e13-e29.	5.6	314
8	Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome. Blood, 2018, 131, 1442-1455.	1.4	288
9	Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. Journal of Allergy and Clinical Immunology, 2017, 139, 1698-1701.	2.9	282
10	An immune-based biomarker signature is associated with mortality in COVID-19 patients. JCI Insight, 2021, 6, .	5.0	269
11	Molecular Mechanisms in Genetically Defined Autoinflammatory Diseases: Disorders of Amplified Danger Signaling. Annual Review of Immunology, 2015, 33, 823-874.	21.8	230
12	The <scp>NLRC</scp>4 Inflammasome. Immunological Reviews, 2018, 281, 115-123.	6.0	230
13	Pediatric hemophagocytic lymphohistiocytosis. Blood, 2020, 135, 1332-1343.	1.4	226
14	Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood, 2016, 127, 1666-1675.	1.4	207
15	A20 haploinsufficiency (HA20): clinical phenotypes and disease course of patients with a newly recognised NF-kB-mediated autoinflammatory disease. Annals of the Rheumatic Diseases, 2018, 77, 728-735.	0.9	176
16	Distinct interferon signatures and cytokine patterns define additional systemic autoinflammatory diseases. Journal of Clinical Investigation, 2020, 130, 1669-1682.	8.2	142
17	Emergent high fatality lung disease in systemic juvenile arthritis. Annals of the Rheumatic Diseases, 2019, 78, 1722-1731.	0.9	122
18	A novel Pyrin-Associated Autoinflammation with Neutrophilic Dermatosis mutation further defines 14-3-3 binding of pyrin and distinction to Familial Mediterranean Fever. Annals of the Rheumatic Diseases, 2017, 76, 2085-2094.	0.9	118

#	Article	IF	Citations
19	Arthropathy of neonatal onset multisystem inflammatory disease (NOMID/CINCA). Pediatric Radiology, 2007, 37, 145-152.	2.0	116
20	Making Sense of the Cytokine Storm: A Conceptual Framework for Understanding, Diagnosing, and Treating Hemophagocytic Syndromes. Pediatric Clinics of North America, 2012, 59, 329-344.	1.8	115
21	NLRC4 inflammasomopathies. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 398-404.	2.3	97
22	Interferonâ€Î³ Mediates Anemia but Is Dispensable for Fulminant Tollâ€like Receptor 9â€“Induced Macrophage Activation Syndrome and Hemophagocytosis in Mice. Arthritis and Rheumatism, 2013, 65, 1764-1775.	6.7	93
23	Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1Î² inhibition. Journal of Allergy and Clinical Immunology, 2019, 144, 1122-1125.e6.	2.9	85
24	IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology, 2020, 59, 361-366.	1.9	73
25	Not all hemophagocytes are created equally. Current Opinion in Rheumatology, 2012, 24, 113-118.	4.3	56
26	Autoinflammatory mutation in NLRC4 reveals a leucine-rich repeat (LRR)â€“LRR oligomerization interface. Journal of Allergy and Clinical Immunology, 2018, 142, 1956-1967.e6.	2.9	52
27	Convergent pathways of the hyperferritinemic syndromes. International Immunology, 2018, 30, 195-203.	4.0	50
28	IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome. Rheumatology, 2020, 59, 442-445.	1.9	50
29	Adenosine deaminase 2 as a biomarker of macrophage activation syndrome in systemic juvenile idiopathic arthritis. Annals of the Rheumatic Diseases, 2020, 79, 225-231.	0.9	50
30	Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles. Annals of the Rheumatic Diseases, 2022, 81, 406-415.	0.9	49
31	Immunodeficiency and bone marrow failure with mosaic and germline TLR8 gain of function. Blood, 2021, 137, 2450-2462.	1.4	47
32	Proteomic profiling of MIS-C patients indicates heterogeneity relating to interferon gamma dysregulation and vascular endothelial dysfunction. Nature Communications, 2021, 12, 7222.	12.8	41
33	Highways to hell: Mechanism-based management of cytokine storm syndromes. Journal of Allergy and Clinical Immunology, 2020, 146, 949-959.	2.9	39
34	Acute hepatitis in three patients with systemic juvenile idiopathic arthritis taking interleukin-1 receptor antagonist. Pediatric Rheumatology, 2009, 7, 21.	2.1	28
35	A novel de novo NLRC4 mutation reinforces the likely pathogenicity of specific LRR domain mutation. Clinical Immunology, 2020, 211, 108328.	3.2	24
36	DDX17 is an essential mediator of sterile NLRC4 inflammasome activation by retrotransposon RNAs. Science Immunology, 2021, 6, eabi4493.	11.9	24

#	Article	IF	Citations
37	Identification of Distinct Inflammatory Programs and Biomarkers in Systemic Juvenile Idiopathic Arthritis and Related Lung Disease by Serum Proteome Analysis. Arthritis and Rheumatology, 2022, 74, 1271-1283.	5.6	24
38	Interleukin-18 and cytotoxic impairment are independent and synergistic causes of murine virus-induced hyperinflammation. Blood, 2020, 136, 2162-2174.	1.4	20
39	Excess Serum Interleukinâ€18 Distinguishes Patients With Pathogenic Mutations in <scp>PSTPIP1</scp>. Arthritis and Rheumatology, 2022, 74, 353-357.	5.6	19
40	Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials. Critical Care, 2022, 26, 128.	5.8	18
41	Brief Report: Alternative Activation of Laserâ€Captured Murine Hemophagocytes. Arthritis and Rheumatology, 2014, 66, 1666-1671.	5.6	17
42	Comprehensive Serum Proteome Profiling of Cytokine Release Syndrome and Immune Effector Cellâ€“Associated Neurotoxicity Syndrome Patients with B-Cell ALL Receiving CAR T19. Clinical Cancer Research, 2022, 28, 3804-3813.	7.0	17
43	Intestinal IL-17R Signaling Constrains IL-18-Driven Liver Inflammation by the Regulation of Microbiome-Derived Products. Cell Reports, 2019, 29, 2270-2283.e7.	6.4	16
44	Editorial: Interferonâ€Î³: Friend or Foe in Systemic Juvenile Idiopathic Arthritis and Adultâ€Onset Still's Disease?. Arthritis and Rheumatology, 2014, 66, 1072-1076.	5.6	14
45	A 17 year old with isolated proximal tibiofibular joint arthritis. Pediatric Rheumatology, 2013, 11, 1.	2.1	12
46	IL-10 distinguishes a unique population of activated, effector-like CD8+ T cells in murine acute liver inflammation. Journal of Leukocyte Biology, 2017, 101, 1037-1044.	3.3	11
47	Sepsis with liver dysfunction and coagulopathy predicts an inflammatory pattern of macrophage activation. Intensive Care Medicine Experimental, 2022, 10, 6.	1.9	11
48	No shortcuts: new findings reinforce why nuance is the rule in genetic autoinflammatory syndromes. Current Opinion in Rheumatology, 2017, 29, 506-515.	4.3	6
49	Chronic, Systemic Interleukin-18 Does Not Promote Macular Degeneration or Choroidal Neovascularization. , 2017, 58, 1764.		3
50	NEMO-NDAS: A Panniculitis in the Young Representing an Autoinflammatory Disorder in Disguise. American Journal of Dermatopathology, 2022, 44, e64-e66.	0.6	3
51	IL-1 receptor antagonist, MIS-C, and the peculiar autoimmunity of SARS-CoV-2. Lancet Rheumatology, The, 2022, 4, e305-e307.	3.9	2
52	Reply. Journal of Allergy and Clinical Immunology, 2017, 140, 316-317.	2.9	1
53	Introduction: Autoinflammatory Syndromes Special Issueâ€”hidden mysteries in the corners of autoinflammation. International Immunology, 2018, 30, 181-182.	4.0	1
54	Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2. Journal of Clinical Immunology, 2021, 41, 987-991.	3.8	1

#	Article	IF	Citations
55	Other Rare Monogenic Autoinflammatory Diseases. , 2019, , 515-538.		0
56	Reply. Arthritis and Rheumatology, 2021, 73, 1342-1343.	5.6	0
57	The Intersections of Autoinflammation and Cytokine Storm. , 2019, , 407-421.		0
58	NLRC4-Associated Autoinflammatory Diseases. , 2020, , 511-516.		0